Yao Xin, Cai Haomin, Chen Jianxia, Yu Fangyong, Wu Xiaocui, Shi Yarong, Hu Yang, Xu Yuyan, Xu Qinghua, Liu Zhonghua
Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, China.
Front Immunol. 2025 Mar 18;16:1545537. doi: 10.3389/fimmu.2025.1545537. eCollection 2025.
T cells are crucial in controlling Mycobacterium tuberculosis infection and disease progression. Nevertheless, the specific functions and changes of T lymphocyte subsets in retreatment tuberculosis remain poorly understand. The study aims to identify the changes in T lymphocyte subsets and the immunoprotective effect of T in retreatment tuberculosis.
We collected venous blood from the participants and assessed using flow cytometry. Univariate analysis and regression model were used to evaluate the changes of T lymphocyte subsets and key subsets in retreatment tuberculosis.
In the study, while the frequencies of CD4 and CD8 T cells were similar between primary and retreatment patients, retreatment patients exhibited a significant increase in T ( < 0.05), which may represent a protective factor for retreatment (adjusted OR=0.926, 95%CI: 0.860-0.996, < 0.05) (adjusted OR=0.951, 95%CI: 0.912-0.992, <0.05). Furthermore, T significantly increased in retreatment patients who achieved cure ( < 0.05), though were similar between the cure and no-cure for primary patients; The potentially protective effect of T in patients with repeated infection may possibly contribute by improving the efficacy of retreatment chemotherapy (adjusted OR=0.803, 95%CI: 0.677-0.953, < 0.05) (adjusted OR=0.890, 95% CI: 0.812-0.976, <0.05), particularly in those with lung injury (adjusted OR=0.780, 95% CI: 0.635-0.957, < 0.05) (adjusted OR=0.805, 95% CI: 0.660-0.983, <0.05).
Development of adjunct immunotherapies for increasing T responses may improve the efficacy of retreatment tuberculosis with existing and with novel chemotherapies.
T细胞在控制结核分枝杆菌感染和疾病进展中起关键作用。然而,复治结核病中T淋巴细胞亚群的具体功能和变化仍知之甚少。本研究旨在确定复治结核病中T淋巴细胞亚群的变化以及T细胞的免疫保护作用。
我们收集了参与者的静脉血并使用流式细胞术进行评估。采用单因素分析和回归模型评估复治结核病中T淋巴细胞亚群和关键亚群的变化。
在本研究中,初治患者和复治患者的CD4和CD8 T细胞频率相似,但复治患者的T细胞显著增加(P<0.05),这可能是复治的一个保护因素(校正OR=0.926,95%CI:0.860-0.996,P<0.05)(校正OR=0.951,95%CI:0.912-0.992,P<0.05)。此外,治愈的复治患者中T细胞显著增加(P<0.05),而初治患者治愈组和未治愈组之间T细胞相似;T细胞在反复感染患者中的潜在保护作用可能通过提高复治化疗的疗效来实现(校正OR=0.803,95%CI:0.677-0.953,P<0.05)(校正OR=0.890,95%CI:0.812-0.976,P<0.05),特别是在有肺损伤的患者中(校正OR=0.780,95%CI:0.635-0.957,P<0.05)(校正OR=0.805,95%CI:0.660-0.983,P<0.05)。
开发辅助免疫疗法以增强T细胞反应可能会提高现有和新型化疗方案治疗复治结核病的疗效。